BONEH BBS-Bioactive Bone Substitutes Oyj

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)

BBS Bioactive Bone Substitutes Oyj  - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Jalovaara, Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220826100002_2

____________________________________________

Transaction date: 2022-05-23

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 55,862 Unit price: 0.0121 EUR

Aggregated transactions

(1): Volume: 55,862 Volume weighted average price: 0.0121 EUR

____________________________________________

Transaction date: 2022-05-24

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 165,492 Unit price: 0.0085 EUR

Aggregated transactions

(1): Volume: 165,492 Volume weighted average price: 0.0085 EUR

____________________________________________

Transaction date: 2022-05-25

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 4,662 Unit price: 0.006 EUR

(2): Volume: 61,786 Unit price: 0.0043 EUR

Aggregated transactions

(2): Volume: 66,448 Volume weighted average price: 0.00442 EUR

____________________________________________

Transaction date: 2022-05-27

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 142,848 Unit price: 0.0013 EUR

(2): Volume: 71,400 Unit price: 0.0013 EUR

(3): Volume: 17,850 Unit price: 0.0013 EUR

Aggregated transactions

(3): Volume: 232,098 Volume weighted average price: 0.0013 EUR

For more information:

Ilkka Kangasniemi, CEO,

tel. , e-mail:

Liisa Hukka, CFO,

tel. , e-mail:

Certified Advisor:

Nordic Certified Adviser AB, tel. 9,

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: -artebone.fi



EN
31/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BBS-Bioactive Bone Substitutes Oyj

 PRESS RELEASE

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. BBS is currently in the process of searching for a new in-house CFO. The appoi...

 PRESS RELEASE

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä BBS-Bioactive Bone Substitutes Oyj, yhtiötiedote, 6.3.2024 klo 11:15 Muutos BBS-Bioactive Bone Substitues Oyj:n johtoryhmässä Oy JAMERCO Ltd. on tänään irtisanonut palvelusopimuksen BBS-Bioactive Bone Substitutes Oyj:n (BBS) kanssa, minkä seurauksena Jari Kortesluoman tehtävä BBS:n talousjohtajana ja johtoryhmän jäsenenä päättyy. Jari Kortesluoma jatkaa BBS:n talousjohtajan tehtävien hoitamista kahden kuukauden irtisanomisajan puitteissa. BBS hakee uutta työsuhteista talouspäällikköä ja nimityksestä tiedotetaa...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023...

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited) BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at . Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTS In the secon...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallis...

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallisen vaiheen valmistelut alkaneet (tilintarkastamaton) BBS-Bioactive Bone Substitutes Oyj, Tilinpäätöstiedote, 26.2.2024 klo 17.45 Tämä tiedote on tiivistelmä BBS-Bioactive Bone Substitutes Oyj:n tilinpäätöstiedotteesta tammi–joulukuu 2023. Koko raportti on tämän yhtiötiedotteen liitteenä pdf-tiedostona. Raportti on saatavilla myös BBS-Bioactive Bone Substitutes Oyj:n verkkosivuilla osoitteessa. Kaupallisen vaiheen valmistelut alkaneet HEINÄ-JOULUKUU Vuoden 2023 toisella puoliskolla BBS eteni merkittävästi ensimmäisen ...

 PRESS RELEASE

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of a...

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch